

# Andrew C Hooker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3677152/publications.pdf>

Version: 2024-02-01

77  
papers

3,643  
citations

236612

25  
h-index

133063

59  
g-index

78  
all docs

78  
docs citations

78  
times ranked

4033  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. AAPS Journal, 2021, 23, 33.	2.2	0
2	Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium. Clinical Pharmacology in Drug Development, 2021, 10, 220-228.	0.8	6
3	Pharmacometrics meets statistics—A synergy for modern drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1134-1149.	1.3	9
4	Metaheuristics for pharmacometrics. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1297-1309.	1.3	4
5	Tutorial for \$DESIGN in NONMEM: Clinical Trial Evaluation and Optimization. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	1.3	4
6	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
7	Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model-Based Bioequivalence. Clinical Pharmacology and Therapeutics, 2020, 110, 1190-1195.	2.3	7
8	Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. AAPS Journal, 2020, 22, 98.	2.2	3
9	Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models. AAPS Journal, 2020, 22, 90.	2.2	3
10	Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. AAPS Journal, 2020, 22, 115.	2.2	4
11	Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models. AAPS Journal, 2019, 21, 95.	2.2	2
12	Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology. AAPS Journal, 2018, 20, 39.	2.2	12
13	Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations. AAPS Journal, 2018, 20, 64.	2.2	2
14	Model-Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop. Clinical Pharmacology and Therapeutics, 2018, 104, 27-30.	2.3	17
15	Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes. AAPS Journal, 2018, 20, 24.	2.2	6
16	Reduced and optimized trial designs for drugs described by a target mediated drug disposition model. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 637-647.	0.8	1
17	The Standard Output: A Tool-Agnostic Modeling Storage Format. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 543-546.	1.3	0
18	Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group. AAPS Journal, 2018, 20, 85.	2.2	1

#	ARTICLE	IF	CITATIONS
19	A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim. <i>AAPS Journal</i> , 2018, 20, 91.	2.2	17
20	Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials. <i>Pharmaceutical Research</i> , 2017, 34, 1125-1133.	1.7	15
21	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4 <sup>th</sup> -5 December 2014). <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 418-429.	1.3	52
22	Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 581-597.	0.8	27
23	Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 611-616.	0.8	3
24	Model Description Language (MDL): A Standard for Modeling and Simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 647-650.	1.3	15
25	The effect of using a robust optimality criterion in model based adaptive optimization. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 317-324.	0.8	8
26	Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 87-109.	1.3	261
27	The effect of Fisher information matrix approximation methods in population optimal design calculations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 609-619.	0.8	4
28	Accelerating Monte Carlo power studies through parametric power estimation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 223-234.	0.8	12
29	PopED lite: An optimal design software for preclinical pharmacokinetic and pharmacodynamic studies. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 127, 126-143.	2.6	6
30	Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations. <i>AAPS Journal</i> , 2016, 18, 505-518.	2.2	11
31	A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 127, 83-93.	2.6	42
32	Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 316-319.	1.3	37
33	Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue model. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 116-127.	1.1	1
34	Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 6-17.	1.1	65
35	Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 211-224.	0.8	2
36	Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 639-654.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Simultaneous Pharmacokinetic Modeling of Alkylresorcinols and Their Main Metabolites Indicates Dual Absorption Mechanisms and Enterohepatic Elimination in Humans. <i>Journal of Nutrition</i> , 2014, 144, 1674-1680.	1.3	15
38	Population pharmacometrics in support of analgesics studies. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 143-156.	0.7	7
39	Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 223-238.	0.8	15
40	Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling. <i>Pharmaceutical Research</i> , 2014, 31, 2152-2165.	1.7	61
41	A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 – Estimating occupancy in the absence of a reference region. <i>NeuroImage</i> , 2013, 82, 160-169.	2.1	40
42	Simultaneous optimal experimental design for in vitro binding parameter estimation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 573-585.	0.8	0
43	Optimizing disease progression study designs for drug effect discrimination. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 587-596.	0.8	6
44	Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-2.	1.3	26
45	Chain Length of Dietary Alkylresorcinols Affects Their In Vivo Elimination Kinetics in Rats. <i>Journal of Nutrition</i> , 2013, 143, 1573-1578.	1.3	12
46	Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	1.3	507
47	Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 29-38.	1.0	3
48	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Cyclosporin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 347-360.	1.0	16
49	Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1516-1526.	1.0	8
50	Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 863-871.	2.3	9
51	Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. <i>NeuroImage</i> , 2012, 61, 849-856.	2.1	27
52	PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool. <i>Computer Methods and Programs in Biomedicine</i> , 2012, 108, 789-805.	2.6	61
53	Serial correlation in optimal design for nonlinear mixed effects models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 239-249.	0.8	8
54	Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. <i>AAPS Journal</i> , 2011, 13, 143-151.	2.2	1,057

#	ARTICLE	IF	CITATIONS
55	Multinomial Logistic Functions in Markov Chain Models of Sleep Architecture: Internal and External Validation and Covariate Analysis. <i>AAPS Journal</i> , 2011, 13, 445-463.	2.2	9
56	A Fast Method for Testing Covariates in Population PK/PD Models. <i>AAPS Journal</i> , 2011, 13, 464-72.	2.2	34
57	Optimal Design in Population Kinetic Experiments by Set-Valued Methods. <i>AAPS Journal</i> , 2011, 13, 495-507.	2.2	2
58	Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. <i>Drug Metabolism and Disposition</i> , 2011, 39, 858-863.	1.7	7
59	Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression. <i>Pharmaceutical Research</i> , 2010, 27, 866-877.	1.7	2
60	Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 557-566.	1.1	21
61	Adaptive-Optimal Design in PET Occupancy Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 563-571.	2.3	29
62	Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 323-335.	1.0	9
63	Simultaneous optimal experimental design on dose and sample times. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 125-145.	0.8	34
64	Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 281-295.	0.8	18
65	Modeling Subpopulations with the \$MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making. <i>AAPS Journal</i> , 2009, 11, 148-154.	2.2	31
66	Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 117-137.	0.8	2
67	Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5386-5400.	1.6	26
68	Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 111-118.	2.3	45
69	Population pharmacokinetics of bevacizumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 14570-14570.	0.8	2
70	Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method. <i>Pharmaceutical Research</i> , 2007, 24, 2187-2197.	1.7	282
71	Automated identification of axonal growth cones in time-lapse image sequences. <i>Journal of Neuroscience Methods</i> , 2006, 151, 232-238.	1.3	13
72	Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. <i>AAPS Journal</i> , 2005, 7, E759-E785.	2.2	32

#	ARTICLE	IF	CITATIONS
73	Robust Population Pharmacokinetic Experiment Design. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 33-64.	0.8	42
74	poped, a software for optimal experiment design in population kinetics. <i>Computer Methods and Programs in Biomedicine</i> , 2004, 74, 29-46.	2.6	79
75	An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations. <i>Annals of Biomedical Engineering</i> , 2003, 31, 98-111.	1.3	27
76	Quantitative Magnetic Resonance Imaging Analysis of Neovasculature Volume in Carotid Atherosclerotic Plaque. <i>Circulation</i> , 2003, 107, 851-856.	1.6	340
77	Classical examination of the Stark effect in hydrogen. <i>Physical Review A</i> , 1997, 55, 4609-4612.	1.0	12